GlassScriptPhysician profile
Noah M Sarr
NPI 1114377686
$12,442.73
in general payments reported to CMS, 2019-2025
56 companies · $1,749 in 2025
The $1,749 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,287 · 2022: $3,151 · 2023: $3,009 · 2024: $1,247 · 2025: $1,749.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,004.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,845.47 | 2021-2025 | |
| Novo Nordisk INC | $980.51 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $962.24 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Corcept Therapeutics | $913.31 | 2021-2023 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $652.04 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $618.66 | 2021-2025 | Rexulti |
| Lilly USA, LLC | $604.69 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $597.73 | 2021-2025 | Repatha, Otezla, Evenity |
| Takeda Pharmaceuticals U.S.A., INC. | $536.46 | 2021-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $364.73 | 2022 | |
| Merck Sharp & Dohme LLC | $325.82 | 2021-2025 | Verquvo, Belsomra |
| E.R. Squibb & Sons, L.L.C. | $324.07 | 2022-2025 | Cobenfy |
| Lundbeck LLC | $317.12 | 2021-2025 | Rexulti, Vyepti |
| Axsome Therapeutics, INC. | $304.29 | 2022-2025 | Auvelity |
| Glaxosmithkline, LLC. | $283.94 | 2021-2024 | Trelegy Ellipta |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noah Sarr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.